NASDAQ:ZEAL - Nasdaq - US98920Y3045 - ADR - Currency: USD
NASDAQ:ZEAL (9/29/2022, 8:02:19 PM)
17.59
+0.21 (+1.21%)
The current stock price of ZEAL is 17.59 USD. In the past month the price decreased by -5.35%. In the past year, price decreased by -48.7%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Zealand Pharma AS
Sydmarken 11
Soeborg 2860 DK
CEO: Emmanuel Dulac
Employees: 237
Company Website: https://www.zealandpharma.com/
Phone: 4588773600.0
The current stock price of ZEAL is 17.59 USD. The price increased by 1.21% in the last trading session.
The exchange symbol of Zealand Pharma AS is ZEAL and it is listed on the Nasdaq exchange.
ZEAL stock is listed on the Nasdaq exchange.
14 analysts have analysed ZEAL and the average price target is 28.31 USD. This implies a price increase of 60.93% is expected in the next year compared to the current price of 17.59. Check the Zealand Pharma AS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Zealand Pharma AS (ZEAL) has a market capitalization of 811.25M USD. This makes ZEAL a Small Cap stock.
Zealand Pharma AS (ZEAL) currently has 237 employees.
Zealand Pharma AS (ZEAL) has a support level at 16.62 and a resistance level at 19.15. Check the full technical report for a detailed analysis of ZEAL support and resistance levels.
The Revenue of Zealand Pharma AS (ZEAL) is expected to grow by 13.79% in the next year. Check the estimates tab for more information on the ZEAL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZEAL does not pay a dividend.
Zealand Pharma AS (ZEAL) will report earnings on 2022-11-09.
Zealand Pharma AS (ZEAL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.45).
ChartMill assigns a technical rating of 6 / 10 to ZEAL. When comparing the yearly performance of all stocks, ZEAL is one of the better performing stocks in the market, outperforming 70.51% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ZEAL. ZEAL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ZEAL reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS increased by 3.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -583.94% | ||
ROA | -94.74% | ||
ROE | N/A | ||
Debt/Equity | 0.93 |
ChartMill assigns a Buy % Consensus number of 86% to ZEAL. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -5.24% and a revenue growth 13.79% for ZEAL